Skip to Content

Treating MRD Relapse After First-Line Treatment May Prolong PFS and OS in Myeloma Patients

Frida Bugge Askeland, MD and investigator at Oslo Myeloma Center in Norway, presents the REMNANT Trial in this MEDtalk from her poster at EHA. This trial will evaluate whether treating MRD relapse after first-line treatment will prolong progression-free survival and overall survival in myeloma patients.

Frida Bugge Askeland

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top